glp 1 average weekly weight loss Once-weekly injectable GIP/GLP-1 dual agonist, VK2735, conferred 13-week of: 📌 10.9% with 5 mg 📌 12.9% with 10 mg 📌 14.7% with 15 mg Like similar medications we have, the GLP-1 Agonists In Obesity

Injection technique matters more than most people realize

Limitations Side effects can be more pronounced initially (nausea, diarrhea)

These small changes are the earliest visible signs of the transformation that will accelerate dramatically over the coming months

Body composition analysis during this phase typically shows encouraging ratios

These can include: Digestive issues that could lead to dehydration and cause kidney damage Gastrointestinal issues like pancreatitis or gallbladder disease Low blood pressure Low blood sugar levels There is also a black box warning, the most serious kind from the FDA, on both medications for the risk of a certain rare type of thyroid cancer

Balancing Safety and Progress While working toward your goals, keep an eye on safety